Kyle D. Cobarrubias

Kyle D. Cobarrubias

Auto-generated profile, based on publicly available information

Kyle D. Cobarrubias

Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Viruses
Verified
Journal Article
Open access
PDF file
BTBirkneh Tilahun Tadesse
Birkneh Tilahun Tadesse
NKNatalie Kinloch
Natalie Kinloch
BBBemulu Baraki
Bemulu Baraki
HLHope R. Lapointe
Hope R. Lapointe
KCKyle D. Cobarrubias
Kyle D. Cobarrubias
ZBZabrina L Brumme
Zabrina L Brumme
Clinical monitoring of pediatric HIV treatment remains a major challenge in settings where drug resistance genotyping is not routinely available. As a result, our understanding of drug resistance, and its impact on subsequent therapeutic regimens available in these settings, remains limited. We investigate the prevalence and correlates of HIV-1 drug resistance among 94 participants of the Ethiopia Pediatric HIV Cohort failing first-line combination antiretroviral therapy (cART) using dried blood spot-based genotyping. Overall, 81% (73/90) of successfully genotyped participants harbored resistance mutations, including 69% (62/90) who harbored resistance to both Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs). Strikingly, 42% of resistant participants harbored resistance to all four NRTIs recommended for second-line use in this setting, meaning that there are effectively no remaining cART options for these children. Longer cART duration and prior regimen changes were significantly associated with detection of drug resistance mutations. Replicate genotyping increased the breadth of drug resistance detected in 34% of cases, and thus is recommended for consideration when typing from blood spots. Implementation of timely drug resistance testing and access to newer antiretrovirals and drug classes are urgently needed to guide clinical decision-making and improve outcomes for HIV-infected children on first-line cART in Ethiopia.